Literature DB >> 11380442

Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis.

L E Adinolfi1, M G Giordano, A Andreana, M F Tripodi, R Utili, G Cesaro, E Ragone, E Durante Mangoni, G Ruggiero.   

Abstract

The pathogenesis of thrombocytopenia in chronic hepatitis is not well known. This study evaluated the relationship between liver injury, serum thrombopoietin, splenomegaly and thrombocytopenia in chronic viral hepatitis. Two hundred and nine patients were enrolled, 85 with splenomegaly and 124 without. Thrombocytopenia was present in 71% and 23% of patients with or without splenomegaly respectively. In subjects with low platelet count, those with splenomegaly showed significantly lower platelet numbers than those without splenomegaly. The spleen size correlated with portal hypertension. An inverse correlation between spleen size and platelet count was observed (r = -0.54; P < 0.0001). In patients without splenomegaly, thrombocytopenia was associated with the grade of fibrosis; platelet counts were the highest in patients with fibrosis 0-2, lower in those with grade 3 (P < 0.008) and lowest in those with grade 4 (P < 0.05). These findings were independent of demographic and biochemical characteristics, hepatic necroinflammatory activity, portal hypertension and splenomegaly. Patients with normal platelet counts showed higher thrombopoietin levels than those with low platelet counts (P < 0.0001). An inverse correlation between thrombopoietin levels and fibrosis grade was observed (r = - 0.50; P < 0.0001). Median thrombopoietin levels were 58 and 27 pg/ml for fibrosis grade 0-1 and grade 4 respectively (P < 0.001). These data indicate that advanced hepatic fibrosis, causing an altered production of thrombopoietin and portal hypertension, plays the central role in the pathogenesis of thrombocytopenia in chronic viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380442     DOI: 10.1046/j.1365-2141.2001.02824.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  35 in total

1.  Correlation of aspartate aminotransferase/platelet ratio index with hepatic venous pressure gradient in cirrhosis.

Authors:  Vipin Verma; Shiv Kumar Sarin; Praveen Sharma; Ashish Kumar
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

2.  Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.

Authors:  Kazuaki Tejima; Ryota Masuzaki; Hitoshi Ikeda; Haruhiko Yoshida; Ryosuke Tateishi; Yosuke Sugioka; Yukio Kume; Tomoko Okano; Tomomi Iwai; Hiroaki Gotoh; Sachiko Katoh; Atsushi Suzuki; Yukako Koike; Yutaka Yatomi; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-03-26       Impact factor: 7.527

3.  Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis.

Authors:  Angelo Iacobellis; Matilde Marcellini; Angelo Andriulli; Francesco Perri; Gioacchino Leandro; Rita Devito; Valerio Nobili
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

4.  Dissecting pathways to thrombocytopenia in a mouse model of visceral leishmaniasis.

Authors:  Gulab Fatima Rani; Olivier Preham; Helen Ashwin; Najmeeyah Brown; Ian S Hitchcock; Paul M Kaye
Journal:  Blood Adv       Date:  2021-03-23

5.  Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.

Authors:  Panasiuk Anatol; Flisiak Robert; Prokopowicz Danuta
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

6.  Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery.

Authors:  Matthew C Schwartz; Lisa M Sullivan; Andrew C Glatz; Elizabeth Rand; Pierre Russo; David J Goldberg; Jonathan J Rome; Meryl S Cohen
Journal:  Pediatr Cardiol       Date:  2012-06-14       Impact factor: 1.655

Review 7.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

8.  Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.

Authors:  Kristen M Marks; Robin M A Clarke; James B Bussel; Andrew H Talal; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

9.  Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Authors:  Masahide Fukudo; Takuma Ito; Tomoyuki Mizuno; Keiko Shinsako; Etsuro Hatano; Shinji Uemoto; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Hiroshi Seno; Tsutomu Chiba; Kazuo Matsubara
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

10.  Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease.

Authors:  Mahmoud Saif-Al-Islam; Usama M Abdelaal; Mustafa Adel Younis; Hisham A Alghany Algahlan; Safaa Khalaf
Journal:  Gastroenterol Res Pract       Date:  2021-05-23       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.